Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
2008-6687
2
1
2011
01
01
Radiation Oncology: A Great Treatment for Cancer Patients
1
2
EN
Ahmad
Mosalaei
0000-0002-3986-8865
Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran
mosalaa@gmail.com
https://mejc.sums.ac.ir/article_41891.html
https://mejc.sums.ac.ir/article_41891_9e3a9aa17deb0c97c20c43973123f468.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
2008-6687
2
1
2011
01
01
Chemotherapy-Induced Nausea and Vomiting: The Role of Aprepitant
3
8
EN
Muath
Mohammed
Abu Hilal
School of Nursing, Hashemite University, Az Zarqa, Jordan
rn.muathabuhilal@yahoo.com
Antiemetics are given to cancer patients prior to their chemotherapy sessions to protect them from nausea and vomiting induced by chemotherapy. The responsible health care team member will choose the type of antiemetic required to prevent the patient from developing nausea and vomiting according to the chemotherapy ematogenicity level. Current guidelines recommend using a single antiemetic agent or a combination of antiemetic agents such as a 5-hydroxytrypt-amine3 receptor antagonist, dexamethasone, or the neurokinin-1 receptor antagonist aprepitant. This review discusses the role of aprepitant in preventing and managing nausea and vomiting induced by chemotherapy.
https://mejc.sums.ac.ir/article_41890.html
https://mejc.sums.ac.ir/article_41890_8d1f880bc142fbd4aabf215377fc6636.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
2008-6687
2
1
2011
01
01
Eradication of Established Murine Skin Tumors by Cyclic Chemoimmunotherapy with Cyclophosphamide and Effector T Cells
9
18
EN
Koki
Matsuyama
Division of Respiratory Medicine, Department of Homeostatic Regulation and
Development, Niigata University, Niigata, Japan
hytmt@yahoo.co.jp
Takeshi
Ota
Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan
Junko
Baba
Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan
Takao
Miyabayashi
Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan
Satoshi
Watanabe
Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan
Hiroshi
Kagamu
Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan
Ichiei
Narita
Division of Respiratory Medicine, Department of Homeostatic Regulation and Development, Niigata University, Niigata, Japan
Koh
Nakata
Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan
Hirohisa
Yoshizawa
Bioscience Medical Research Center, Niigata University Medical and Dental Hospital, Niigata, Japan
Background: Nonmyeloablative chemotherapy followed by adoptive immunotherapy is an attractive strategy for depleting regulatory T cells in the host. However, its efficacy is transient. Here, we aim to investigate whether cyclic chemoim- munotherapy has therapeutic efficacy against cancer.Methods:We examined the efficacy of cyclic chemoimmunotherapy with cyclophos- phamide and adoptively transferred effector T cells against 5-day, established MCA205 murine skin sarcomas.Results: Cyclophosphamide administration followed by adoptive immunotherapy augmented the trafficking of effector T cells into established tumors. Further, multiple cyclophosphamide administrations helped effector T cells to persist at the sites. Chemoimmunotherapy achieved complete tumor regression even with the transfer of a limited number of effector T cells (5×106).Conclusion: Cyclic chemoimmunotherapy, which maintains adoptively transferred T cells by impairing regulatory T cells, is a potentially suitable treatment for established tumors.
https://mejc.sums.ac.ir/article_41889.html
https://mejc.sums.ac.ir/article_41889_415d2f51ae81e5540088d9e9f3aa7278.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
2008-6687
2
1
2011
01
01
Increased IL-17 and IL-6 Transcripts in Peripheral Blood Mononuclear Cells: Implication for a Robust Proinflammatory Response in Early Stages of Breast Cancer
19
26
EN
Mansooreh
Jaberipour
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
jaberim@sums.ac.ir
Rasoul
Baharlou
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
Ahmad
Hosseini
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
Abdolrasoul
Talei
0000-0001-9111-3681
Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran
taleiar@gmail.com
Mahboobeh
Razmkhah
Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran
mrazmkhah2@gmail.com
Abbas
Ghaderi
0000-0003-0849-3375
Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran
ghaderia@sums.ac.ir
Background: Several recent studies demonstrated that transforming growth factor beta (TGF-β), by stimulating T regulatory cells, and interleukins 6 and 17 (IL-6, IL- 17), by inducing inflammatory reactions, may be critical factors in cancer pathogenesis.Methods: We used quantitative real-time polymerase chain reaction assays to quantify the expression of IL-17, IL-6 and TGF-β mRNA in peripheral blood mononuclear cells and lymphocytes from draining lymph nodes of 60 women with breast cancer. The results were compared according to the patients’ clinical or pathological status.Results: Higher amounts of IL-17 and IL-6 mRNA, but not TGF-β transcripts, were found in patients compared to controls. There were no significant differences between patients with negative or positive nodes or with different histological grades or stages of disease.Conclusion: Most women in this analysis had stage I or II disease. We thus conclude that IL-17, a prominent proinflammatory cytokine, may play an important role in recruiting and infiltrating antitumor immune responses in early stages of breast cancer.
https://mejc.sums.ac.ir/article_41892.html
https://mejc.sums.ac.ir/article_41892_f8532a58929f6f64539516e7f6fd772e.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
2008-6687
2
1
2011
01
01
The Protective Effect of β-Thalassemia Trait Against Childhood Malignancies in an Unselected Iranian Population
27
31
EN
Mahdi
Shahriari
0000-0001-5104-9590
Division of Pediatric Hematology Oncology, Department of Pediatrics,
Shiraz University of Medical Sciences, Shiraz, Iran
shahryar@sums.ac.ir
Hamid-Reza
Alidoost
Division of Pediatric Hematology Oncology, Department of Pediatrics,
Shiraz University of Medical Sciences, Shiraz, Iran
Background: β-thalassemia trait is one of the most common genetic disorders in Mediterranean countries. Previous studies have shown that β- thalassemia trait has a protective effect against malaria, coronary artery disease, hypertension and Alzheimer disease. We hypothesize that due to the shorter life span of red blood cells and increased hematopoiesis, these patients are at increased risk of developing hematological malignancies. Thus, this study investigated the possible effect of β-thalassemia trait on childhood malignancies.Methods: This was a case-control study that included 432 children with malignancies (leukemias and lymphomas as well as solid tumors) as the case group and 432 healthy individuals who referred for premarital β-thalassemia trait screening as the control group. All patients underwent a complete blood count as well as hemoglobin electrophoresis. Hemoglobin A2≥3.5% or hemoglobin F between 2% and 10% were considered diagnostic for β- thalassemia trait. The results were compared between groups with the chi-squared test.Results: Mean age of the patients was 7.08 ± 5.1 years and mean age in the control group was 25.46 ± 7.3 years. There were 253 (58.6%) boys and 179 (41.4%) girls among the patients and 308 (71.3%) men and 124 (28.7%) women among the controls. The prevalence of β-thalassemia trait was 5.6% in the case group and 11.3% in the control group (P=0.001). The mean hemoglobin level was 9.81 ± 3.1 g/dL in those with malignancies and 15.3 ± 1.7 g/dL in healthy individuals (P<0.001).Conclusion: β-thalassemia trait is a protective factor against developing childhood malignancies in an unselected Iranian population. However, more studies are needed to clarify this issue.
https://mejc.sums.ac.ir/article_41888.html
https://mejc.sums.ac.ir/article_41888_723fe7c53cb0d3e656579453591f3a63.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
2008-6687
2
1
2011
01
01
Simultaneous Occurrence of Advanced Neuroblastoma and Acute Lymphoblastic Leukemia: A Case Report
33
36
EN
Mohammad
Pedram
Thalassemia & Hemoglobinopathy Research Center, Ahvaz Jondishapur University of
Medical Sciences, Ahvaz, Iran
m_pedram_2007@yahoo.com
Majid
Vafaie
Shafa Hospital, Ahvaz Jondishapur University of Medical Sciences, Ahvaz, Iran
Kaveh
Jaseb
Shafa Hospital, Ahvaz Jondishapur University of Medical Sciences, Ahvaz, Iran
Kiavash
Fekri
Shafa Hospital, Ahvaz Jondishapur University of Medical Sciences, Ahvaz, Iran
Sabahat
Haghi
Shafa Hospital, Ahvaz Jondishapur University of Medical Sciences, Ahvaz, Iran
Neuroblastoma is the most common extracranial solid tumor in children. The co- occurrence of neuroblastoma and acute lymphoblastic leukemia is rare. We report a rare case of advanced-stage neuroblastoma in a 3.5-year-old girl that was accompanied by acute lymphoblastic leukemia following treatment. Her leukemia may have been due to chemotherapy (secondary leukemia) or may have been de novo.
https://mejc.sums.ac.ir/article_41887.html
https://mejc.sums.ac.ir/article_41887_ea690ccc96b88ab08e95d0439bc530fa.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
2008-6687
2
1
2011
01
01
Osteopoikilosis: A Sign Mimicking Skeletal Metastases in a Cancer Patient
37
41
EN
Sepideh
Sefidbakht
Department of Radiology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Yaghoub
Ashouri-Taziani
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Sareh
Hoseini
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Mansour
Ansrai
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Niloofar
Ahmadloo
0000-0003-3178-8577
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
ahmadloon@gmail.com
Ahmad
Mosalaei
0000-0002-3986-8865
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
mosalaa@gmail.com
Shapour
Omidvari
0000-0003-3656-9891
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
omidvari@sums.ac.ir
Hamid
Nasrolahi
Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
nasrolahi.hamid@gmail.com
Mohammad
Mohammadianpanah
0000-0001-9391-8977
Department of Radiology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
mohpanah@gmail.com
Osteopoikilosis is a rare benign osteosclerotic bone disorder that may be misdiagnosed as skeletal metastases. Here we describe a case of coincidental breast cancer and osteopoikilosis mimicking skeletal metastases. A 41-year-old woman underwent right modified radical mastectomy in April 2007. Twenty-eight months after initial treatment, the patient complained of bilateral knee and foot pain. Plain X-rays of the feet and knees showed multiple well-defined osteosclerotic lesions. According to the radiographic appearance, the most likely differential diagnoses included skeletal metastases from breast cancer and osteopoikilosis. A whole-body bone scintigraphy showed no increase in uptake by the sclerotic lesions, and serum lactic dehydrogenase, carcinoembryon- ic antigen, alkaline phosphatase and cancer antigen 15-3 were not elevated. We therefore diagnosed the patient’s skeletal lesions as osteopoikilosis. This case and our literature review suggest that the radiographic appearance of osteopoikilosis may mimic or mask skeletal metastases, potentially leading to misdiagnosis in patients with cancer.
https://mejc.sums.ac.ir/article_41893.html
https://mejc.sums.ac.ir/article_41893_c6e63d63a885dbe03922557dc774ad70.pdf
Shiraz University of Medical Sciences
Middle East Journal of Cancer
2008-6709
2008-6687
2
1
2011
01
01
Large Neurofibroma of the Anorectal Canal: A Case Report
43
47
EN
Leila
Ghahramani
0000-0002-5282-2212
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
leila_ghahramani@yahoo.com
Ahmad
Izadpanah
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
hosseiniv@yahoo.com
Ali Mohammad
Bananzadeh
0000-0003-1116-2294
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
bananzadeh@gmail.com
Majid
Akrami
0000-0001-6627-2648
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
akramimd@yahoo.com
Faranak
Bahrami
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Seyed Vahid
Hosseini
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
hoseiniv@sums.ac.ir
Neurofibromatosis type 1, also known as von Recklinghausen disease, is an autosomal dominant disorder with an incidence of 1 per 4000. Neurofibromas are benign, heterogeneous tumors arising from the connective tissue of peripheral nerve sheaths, especially the endoneurium. Visceral involvement in disseminated neurofibromatosis is rare. Neurofibroma occurs most frequently in the stomach and jejunum, but the colon and anorectal canal may also be involved. Gastrointestinal neurofibromas may lead to bleeding, obstruction, intussusception, protein-losing enteropathy and bowel perforation. We present a case of diffuse involvement of the anorectal area by a huge neurofibroma, with pelvic pain, watery diarrhea and urgency.
https://mejc.sums.ac.ir/article_41894.html
https://mejc.sums.ac.ir/article_41894_55577f4e2185b6855780d02ab15bbe72.pdf